Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10952765 | 0.84 | NPSR1 (0.53) | GAARAB9ASMN1; SMN2HTT | |
| SCHEMBL5598097 | 0.82 | MEN1 (0.54) | LMNAKMT2AMEN1SMN1; SMN2POLB | |
| SCHEMBL13966687 | 0.79 | NPC1 (0.53) | KMT2AMEN1GAARAB9ASMN1; SMN2 | |
| SCHEMBL2403850 | 0.79 | MEN1 (0.62) | LMNAKMT2AMEN1GAARAB9A | |
| SCHEMBL12319372 | 0.79 | POLB (0.42) | LMNAKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL10951354 | 0.78 | TSHR (0.63) | KMT2AMEN1GAARAB9ASMN1; SMN2 | |
| SCHEMBL12446562 | 0.75 | GAA (0.58) | KMT2AMEN1GAARAB9ASMN1; SMN2 | |
| SCHEMBL334233 | 0.75 | BCHE (0.61) | LMNABCHEGAARAB9ASMN1; SMN2 | |
| SCHEMBL25528958 | 0.73 | TSHR (0.65) | LMNAKMT2AMEN1BCHEGALR3 | |
| SCHEMBL31345023 | 0.73 | MEN1 (0.51) | LMNAKMT2AMEN1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907109-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | IMMUNOLIGHT, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8907109-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | IMMUNOLIGHT, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8907109-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | IMMUNOLIGHT, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8791275-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | DUKE UNIVERSITY (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791275-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | DUKE UNIVERSITY (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791275-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | DUKE UNIVERSITY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130129757-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131429-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | lmmunolight, LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131429-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | lmmunolight, LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131429-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | lmmunolight, LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129757-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129757-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-8383836-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | DUKE UNIVERSITY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383836-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | DUKE UNIVERSITY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383836-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | DUKE UNIVERSITY (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2010123996-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100266621-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | DUKE UNIVERSITY (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100266621-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | DUKE UNIVERSITY (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100266621-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | DUKE UNIVERSITY (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266621-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | CDK20, NFATC1, CDK10 | LMNA 878/4885KMT2A 2284/4885MEN1 467/4885 |
| US-20130131429-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | CDK20, NFATC1, CDK10 | LMNA 878/4885KMT2A 2284/4885MEN1 467/4885 |
| US-20130129757-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | CDK20, NFATC1, CDK10 | LMNA 878/4885KMT2A 2284/4885MEN1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.